Pacer Advisors Inc. trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 36.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 393,733 shares of the biopharmaceutical company’s stock after selling 227,068 shares during the period. Pacer Advisors Inc.’s holdings in Catalyst Pharmaceuticals were worth $9,190,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of CPRX. Advisory Services Network LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $40,000. Clearstead Advisors LLC boosted its position in Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 1,167 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the last quarter. Finally, Financial Life Planners purchased a new stake in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $42,000. 79.22% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
CPRX has been the subject of several analyst reports. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.
Catalyst Pharmaceuticals Stock Performance
CPRX opened at $31.38 on Monday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The company’s 50 day simple moving average is $29.80 and its 200 day simple moving average is $25.93. The stock has a market capitalization of $3.84 billion, a PE ratio of 18.03, a P/E/G ratio of 0.95 and a beta of 0.74.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.
The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).
Featured Articles
- Five stocks we like better than Catalyst Pharmaceuticals
- 3 Inflation-Fighting Stocks Built for Higher Oil Prices
- 3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally?
- 3 Small-Cap Stocks Getting a Russell 2000 Rebalance Boost
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
